$UFPT

UFP TECHNOLOGIES INC

UFP Technologies is a contract development and manufacturing organization specializing in single-use and single-patient medical devices and components for medical device manufacturers. Its products serve applications including minimally invasive surgery, infection prevention, wound care, wearables, orthopedics, interventional and surgical care, therapeutics, diagnostics, and biopharma. Custom products include surgical and endoscopic disposables, protective drapes, wound care products, medical device packaging, and components for implants and catheters. UFP Technologies earns money by developing and manufacturing products to customer specifications, and sells principally through a direct sales force. Its manufacturing processes include molding, cutting, forming, welding, laminating, and assembly. The company has nineteen manufacturing locations that are ISO 13485 certified and thirteen that are FDA registered. It is headquartered in Newburyport, Massachusetts.

AlphAI earnings readthird quarter ended September 30, 2026 · NOV 3UFP Technologies Announces Strong Q3 ResultsVerdict: strong

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

No enriched coverage for $UFPT in the last 7 days.

No SEC Form 4 filings for $UFPT in the last 30 days.

See all $UFPT insider activity →
Med

UFP Technologies Earnings Call Highlights Growth and Investment

UFP Technologies reported Q3 sales growth of 11.6% to $172.4M, driven by MedTech demand. Gross margin improved to 29.4%, and adjusted EPS rose to $2.88. The company highlighted capacity investments and acquisitions, including CI Medical. Challenges include AJR transfer delays and higher SG&A costs. Management expects long-term growth of 6-9% organically and 12-18% with acquisitions, with a softer fourth quarter.

GoodRx, Evolent Health, UFP Technologies, Centene, and HCA Healthcare shares skyrocket, what you need to know

Shares of GoodRx, Evolent Health, UFP Technologies, Centene, and HCA Healthcare surged after Democrats regained majorities in Congress, easing drug pricing policy concerns. Analysts expect the biopharmaceutical sector to benefit from reduced regulatory uncertainty. UFP Technologies, up 21.5%, has seen significant volatility and strong performance, including a 51.1% year-to-date gain.

UFPT sentiment & insider activity

Recent UFPT coverage spans earnings, market movers and financial news.

What's driving UFPT

AlphAI scores every news story that mentions UFPT with an AI model for sentiment and relevance, and aggregates insider trades from UFP TECHNOLOGIES INC's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $UFPT

Score

UFP Technologies Earnings Call Highlights Growth and Investment

UFP Technologies reported Q3 sales growth of 11.6% to $172.4M, driven by MedTech demand. Gross margin improved to 29.4%, and adjusted EPS rose to $2.88. The company highlighted capacity investments and acquisitions, including CI Medical. Challenges include AJR transfer delays and higher SG&A costs. Management expects long-term growth of 6-9% organically and 12-18% with acquisitions, with a softer fourth quarter.

GoodRx, Evolent Health, UFP Technologies, Centene, and HCA Healthcare shares skyrocket, what you need to know

Shares of GoodRx, Evolent Health, UFP Technologies, Centene, and HCA Healthcare surged after Democrats regained majorities in Congress, easing drug pricing policy concerns. Analysts expect the biopharmaceutical sector to benefit from reduced regulatory uncertainty. UFP Technologies, up 21.5%, has seen significant volatility and strong performance, including a 51.1% year-to-date gain.

UFP Technologies (NASDAQ:UFPT) delivers impressive Q3 2026

UFP Technologies (UFPT) reported Q3 2026 revenue of $172.4M, up 11.6% YoY and 3.2% above estimates. Adjusted EPS of $2.88 beat estimates by 7.3%. Operating margin held steady at 16%. The company cited operational improvements and growth in new programs. Analysts expect 5.6% revenue growth over the next 12 months.

$UFPTHighEarnings

UFP Technologies Announces Strong Q3 Results

UFP TECHNOLOGIES INC (UFPT) filed an SEC Form 8-K — Results of Operations and Financial Condition. UFP Technologies Announces Strong Q3 Results Newburyport, Mass., November 3, 2026. UFP Technologies, Inc. (Nasdaq: UFPT), a trusted contract development and manufacturing organization specializing in comprehensive solutions for medical devices, sterile packaging and other highly

Drug Development Inputs & Services Stocks Q2 In Review: Charles River Laboratories (NYSE:CRL) Vs Peers

Azenta reported Q2 revenue of $161.2M, up 12% YoY, beating estimates. IQVIA reported $4.37B revenue, up 8.7% YoY, exceeding expectations. UFP Technologies reported $174M revenue, up 15.1% YoY, with the largest analyst estimate beat. West Pharmaceutical Services reported $872.3M revenue, up 13.8% YoY, topping expectations. All stocks have seen post-earnings gains.

Q2 Earnings Roundup: UFP Technologies (NASDAQ:UFPT) And The Rest Of The Drug Development Inputs & Services Segment

Azenta reported Q2 revenues of $161.2M, up 12% YoY, beating estimates. IQVIA reported $4.37B in revenues, up 8.7% YoY, exceeding expectations. Charles River Laboratories reported $1.00B in revenues, down 2.7% YoY, but beating estimates. Repligen reported $204.1M in revenues, up 11.9% YoY, also beating estimates. All stocks have seen significant gains since reporting.

Is UFP Technologies (UFPT) Undervalued After Argus Lifted Its Price Target?

Argus raised its price target for UFP Technologies (UFPT) to $334, citing strong recent performance and growth prospects. The stock has gained 34.60% year-to-date and 54.03% over one year. Analysts estimate a fair value of $355, but the stock trades at a P/E of 32.2x, higher than its industry average. The company's expansion and medical sector focus drive optimism, though risks include customer concentration and integration challenges.

Related tickers